Slow progress is still progress, and although AngioDynamics ( ANGO ) arguably still does not get its due in the market, the company continues to execute at an improved level. Solid growth in the faster-growing Medical Tech segment remains the key driver, as theAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am ...